Table 1.
Basic characteristics of the included studies.
| Authors [ref] | Sample Size (T/C) Type of patients | Age(years) T/ C | Course of disease (days)T/C | Intervention | Course of Treatment (days) | Outcome | Adverse events |
|---|---|---|---|---|---|---|---|
| Ding 24 | 100(51/49)mild ordinary severe | 54.7 ± 21.3/50.8 ± 23.5 | 5.3 ± 3.1/6.0 ± 3.7 | Qingfei touxie fuzheng decoction + WM* vs. WM | 10 | (1) Defervescence rate; (2) Cough resolution rate; (3) Tachypnea resolution rate; (4) Diarrhea resolution rate; (6) Adverse event | Abnormal liver function (T:2;C:3) |
| Duan 25 | 123(82/41)mild | 52.0 ± 13.9/50.3 ± 13.2 | 2.7 ± 1.6/2.5 ± 1.5 | Jinhua qinggan granules + WM vs. WM | 5 | (1) Clinical symptoms score; (2) Number of patients turned to the types of severe and critical; (3) Defervescence rate (4) Cough resolution rate; (5) Fatigue resolution rate; (6) Diarrhea resolution rate; (7) Body pain resolution rate; (8) Adverse event | Gastrointestinal reaction (T:27) |
| Fu_a26 | 73(37/36) ordinary |
45.3 ± 7.3/44.7 ± 7.5 | 7.6 ± 1.3/8.5 ± 1.4 | Toujie quwen granules + WM vs. WM | 15 | (1) Number of patients turned to the types of severe and critical; (2) Adverse event | NR in details |
| Fu_b27 | 65(32/33) mild ordinary | 43.3 ± 7.2/43.7 ± 6.5 | 7.56 ± 1.3/8.5 ± 1.6 | Toujie quwen granules + WM vs. WM | 10 | (1) Number of patients turned to the types of severe and critical; (2) Adverse event. | NR in details |
| Hu 28 | 284(142/142) mild ordinary | 50.4 ± 15.2/51.8 ± 14.8 | 9.5 ± 5.1/9.9 ± 5.9 | Lianhua qingwen granules + WM vs. WM | 14 | (1) Rate of 2019-nCoV RT-PCR turned to negativity; (2) Number of patients turned to the types of severe and critical; (3) Adverse event | Gastrointestinal reaction (T:24; C:33); Abnormal liver function (T:32;C:32); Renal dysfunction (T:8;C:11); headache (T:1;C:1) |
| Li 29 | 12(6/6) severe | 52.0 ± 6.6/50.0 ± 10.0 | NR/NR | Qingfei paidu decoction + WM vs. WM | 6 | (1) Length of hospital stay; (2) Adverse event | Pruritus (T:1) |
| Qiu 30 | 50(25/25) ordinary | 53.4 ± 18.4/51.3 ± 14.6 | 2.8 ± 0.8/3.2 ± 1.3 | Maxing Xuanfei Jiedu Decoction + WM vs. WM | 10 | (1) Clinical symptoms score; (2) Number of patients turned to the types of severe and critical; (3) Defervescence time (4) Cough resolution time | Not assessed |
| Sun 31 | 57(32/25) NR | 45.4 ± 14.1/42.0 ± 11.7 | 4.4 ± 2.5/6.0 ± 4.4 | Lianhua qingke granules + WM vs. WM | 14 | (1) Number of patients turned to the types of severe and critical; (2) Defervescence rate; (3) Cough resolution rate; (4) Fatigue resolution rate | Not assessed |
| Xiao 32 | 200(100/100) mild | 60.9 ± 8.7/62.2 ± 7.5 | 5.5 ± 2.09/6.4 ± 3.0 | Sufeng jiedu capsule + WM vs. WM | 14 | (1) Defervescence time; (2) Cough resolution time; (3) Fatigue resolution time; (4) Adverse event | Gastrointestinal reaction (T:2;C:1); Pruritus (T:1; C:2) |
| Ye33 | 42(28/14) severe | 65 (53.5–69)/59 (47–67) | NR/NR | Chinese herbal medicine + WM vs. WM | 7 | (1)Number of patients turned to the types of severe and critical; (2) All-cause death | Not assessed |
| Yu 34 | 295(147/148) mild ordinary | 48.3 ± 9.6/47.3 ± 8.7 | NR/NR | Lianhua qingwen granules + WM vs. WM | 7 | (1) Number of patients turned to the types of severe and critical; (2) All-cause death; (3) Adverse event | NR in details |
T, Treatment group/Experimental group; C, control group; NR, not reported; WM, western medicine; * Western medicine includes antibacterial, antiviral, hormone therapy, respiratory support, etc.